- #ADA26: Pfizer's monthly shot shows effect on obesity, diabetesThe long-acting GLP-1 shot that was the centerpiece of Pfizer’s acquisition of Metsera last year looks effective in patients with both obesity and diabetes, according to data presented Saturday.…Endpoints · 1mo ago↗ source
- #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearRoche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly successful product if…Endpoints · 1mo ago↗ source
- Lawmakers propose China restrictions; #ASCO26 recap; and moreWelcome back to Endpoints Weekly! We had a small team in Chicago last weekend at this year’s ASCO conference. You’ll find a recap of their coverage below, including more details on Revolution Medic…